Inactive

Rituximab One award will be made in the aggregate for line items: 1a and 1b, or 2a and 2b, or 3a and 3b. To be considered for award, offerors must submit a price for the base year and all four one-yea... Rituximab One award will be made in the aggregate for line items: 1a and 1b, or 2a and 2b, or 3a and 3b. To be considered for award, offerors must submit a price for the base year and all four one-year options for all line items. 1a and 1b, or 2a and 2b, or 3a and 3b. Prices offered shall not exceed two decimal places. Offered prices must include the Cost Recovery Fee of 0.5%, as outlined in Scope of Contract. Offerors must list an 11 digit NDC number for each offered drug that is unique to the Offeror's company as outlined in scope of contract. If the offeror is a distributor, the NDC number must be unique to the distributor.

Inactive

PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79720R0045 for an unrestrictive procurement for RITUXIMAB, for the Department of Veterans Aff... PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79720R0045 for an unrestrictive procurement for RITUXIMAB, for the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have a unique NDC number. Solicitation # 36E79720R0045 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about May 28, 2020, with a tentative closing date of June 11, 2020. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: http://www.fedbizopps.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Kenneth Lay Questions can be e-mailed to: Kenneth.Lay@va.gov. The estimated annual requirements are as follows: Item Description Package Size (Vials) Total Estimated Annual Usage (Vials) 1a RITUXIMAB 100MG OR 2a RITUXIMAB-ABBS 100MG 1 21,788 OR 3a RITUXIMAB-PVVR 100MG 1b RITUXAN 500MG OR 2b RITUXIMAB-ABBS 500MG 1 26,793 OR 3b RITUXIMAB-PVVR 500MG